Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. [electronic resource]
Producer: 20150420Description: 442-7 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- analysis
- Breast Neoplasms -- chemistry
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Infusions, Intravenous
- Kaplan-Meier Estimate
- Middle Aged
- Paclitaxel -- administration & dosage
- Receptor, ErbB-2 -- analysis
- Trastuzumab
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.